The Antisera market in Iran saw steady growth between 2013 and 2020, with a slight dip in 2022, likely reflecting external challenges. The market rebounded by 2023, achieving a value of $875.85 million. Over the past five years, the market experienced a modest CAGR of 1.32%, indicating slow but consistent growth. Positive trends were notable in 2021 with a 6.39% increase but faced a temporary decline in 2022.
Future trends to watch for include:
- Potential impacts of economic fluctuations on market value.
- Technological innovations improving efficacy and demand.
- Policy shifts influencing healthcare funding in Iran.
